Aurinia's (AUPH) Profits Surge While Its One Drug Just Got Company
On August 6, Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc. (AUPH)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Tang Capital Management Kevin C. Tang | 13,044,106 | $221,358,479 | +7% | 10.05% |
| 2. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 3,264,062 | $55,391,132 | -1% | 0.02% |
| 3. | Marshall Wace LLP Paul Marshall And Ian Wace | 2,044,007 | $34,686,798 | +10% | 0.03% |
| 4. | Renaissance Technologies Jim Simons | 1,548,035 | $26,270,154 | -7% | 0.04% |
| 5. | D E Shaw D. E. Shaw | 1,408,456 | $23,901,498 | -11% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.28 | 206,005 | $3,147,756.40 | 13,044,106 | 2026-06-02 | Filing | |
| $15.34 | 99 | $1,518.66 | 12,838,101 | 2026-06-01 | Filing | |
| $15.28 | 343,521 | $5,249,000.88 | 12,838,002 | 2026-06-01 | Filing | |
| $15.31 | 262,682 | $4,021,661.42 | 12,494,481 | 2026-05-29 | Filing | |
| $15.35 | 2,299 | $35,289.65 | 12,231,799 | 2026-05-29 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.95 | 11,939 | $190,427.05 | 588,848 | 2026-09-10 | Filing | |
| $16.97 | 20,975 | $355,945.75 | 600,787 | 2026-08-21 | Filing | |
| $10.50 | 20,000 | $210,000.00 | 133,484 | 2025-08-01 | Filing | |
| $8.23 | 8,305 | $68,350.15 | 153,484 | 2025-03-07 | Filing | |
| $7.92 | 164,947 | $1,306,380.24 | 1,788,945 | 2025-03-04 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 368,966 | $5,975,404 | 0.1% | |
| 2. | 217,590 | $3,523,871 | 0.1% | |
| 3. | 62,211 | $1,007,507 | 0.02% | |
| 4. | 32,478 | $525,981 | 0.13% | |
| 5. | 27,373 | $443,990 | 0% |
News See All
Could Aurinia Pharmaceuticals (AUPH) Stock Win Big After its LUPKYNIS Patent Settlement With Teva Pharmaceuticals (TEVA)?
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) and Teva Pharmaceuticals Industries Limited (NYSE:TEVA) reached a major milestone on August 19, settling their U.S. patent dispute.
Is Aurinia Pharmaceuticals Inc. (AUPH) A Good Stock To Buy Now?
Is AUPH a good stock to buy? We came across a bullish thesis on Aurinia Pharmaceuticals Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on AUPH.
Aurinia Pharmaceuticals (AUPH) Reports Financial Results for Three and Twelve Months Ended December 31, 2025
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is one of the best cheap biotech stocks to buy now. Aurinia Pharmaceuticals Inc.
12 Cheap Biotech Stocks to Buy Now
In this article, we will look at the 12 Cheap Biotech Stocks to Buy Now. On February 27, Eli Casdin, Casdin Capital CEO, appeared on CNBC’s ‘Closing Bell’ to talk about the biotech sector.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q4 2025 Earnings Call Transcript
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q4 2025 Earnings Call Transcript February 26, 2026Aurinia Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $1.53, expectations were $0.21.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2025 Earnings Call Transcript
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2025 Earnings Call Transcript November 4, 2025Aurinia Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $0.23, expectations were $0.16.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q2 2025 Earnings Call Transcript
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q2 2025 Earnings Call Transcript July 31, 2025Aurinia Pharmaceuticals Inc. misses on earnings expectations.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2025 Earnings Call Transcript
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2025 Earnings Call Transcript May 12, 2025Aurinia Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $0.16, expectations were $0.08.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q4 2024 Earnings Call Transcript
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q4 2024 Earnings Call Transcript February 27, 2025Aurinia Pharmaceuticals Inc. misses on earnings expectations.
Hedge Fund Resource Center